The Centers for Medicare & Medicaid Services (CMS) has unveiled a significant proposal aimed at streamlining the path for innovative medical devices to reach Medicare beneficiaries. Through a notice with comment period published on August 11, 2026, CMS introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to accelerate national Medicare coverage for eligible new technologies. This move signals CMS's continued effort to address concerns regarding the timeliness of medical device coverage and to foster innovation within the healthcare sector.
A New Approach to Device Coverage
The RAPID pathway targets U.S. Food and Drug Administration (FDA) Breakthrough-designated Class II and Class III devices. These are technologies that often represent significant advancements in patient care. Under the proposed framework, CMS intends to coordinate closely with the FDA, releasing a proposed National Coverage Determination (NCD) concurrently with the FDA's market authorization. This alignment is a key feature, aiming to reduce the lag time between a device's regulatory approval and its Medicare coverage.
Following the proposed NCD, CMS plans to issue a final NCD approximately 60 days later for Class II devices and 90 days later for Class III devices. This expedited timeline contrasts sharply with the traditional NCD process, which typically spans 9 to 12 months. The RAPID pathway specifically leverages the FDA's existing process for assessing clinical outcomes in proposed investigational device exemption (IDE) studies, thereby facilitating a more efficient and streamlined process for manufacturers.
Historical Context and Evolution
The introduction of RAPID comes after considerable feedback from various stakeholders, including beneficiaries, advocacy groups, medical professionals, and device manufacturers. These parties have consistently called for a more flexible, transparent, predictable, and collaborative coverage process. The RAPID pathway reflects insights gathered from the November 15, 2021, repeal of the January 2021 Medicare Coverage of Innovative Technology (MCIT) final rule, and the establishment of the Transitional Coverage for Emerging Technologies (TCET) pathway on August 12, 2024. These previous initiatives underscore a persistent federal interest in accelerating access to promising medical innovations while navigating complex regulatory and evidentiary requirements. RAPID represents the latest iteration in this ongoing evolution.
Medicare, as the largest single healthcare purchaser in the U.S., serves nearly 70 million beneficiaries. In 2025, about 34 million of these beneficiaries were covered by Original Medicare. In fiscal year 2023, Original Medicare processed over 1.1 billion claims, totaling approximately $431.5 billion in benefits. The sheer scale of the program means that changes to its coverage mechanisms have widespread implications for patient access and market dynamics.
Understanding Existing Coverage Mechanisms
To understand the significance of RAPID, it is important to review the existing Medicare coverage landscape. Devices and services are currently covered in three primary ways:
-
Claim-by-Claim Adjudication: This is the most common method, where Medicare Administrative Contractors (MACs) determine coverage on an individual basis, ensuring the item or service is reasonable and necessary for a specific patient. The RAPID pathway does not alter this fundamental standard.
-
Local Coverage Determinations (LCDs): MACs issue LCDs for coverage within their specific jurisdictions, also based on the "reasonable and necessary" standard. LCDs typically take up to a year to finalize.
-
National Coverage Determinations (NCDs): These are national decisions made by the Secretary of Health and Human Services, ensuring uniform coverage across the country. The traditional NCD process is comprehensive but lengthy. NCDs can also be made under the "Coverage with Evidence Development" (CED) pathway, where Medicare covers promising technologies with limited evidence while further research is conducted, often in collaboration with the Agency for Healthcare Research and Quality (AHRQ).
RAPID is designed not to replace these pathways but to create a dedicated, accelerated route for a select group of highly innovative devices, particularly those already designated as Breakthrough Devices by the FDA. This strategic focus aims to provide timely access without compromising the rigorous review standards inherent in Medicare coverage decisions.
Implications and Public Participation
The RAPID pathway has several potential implications. For Medicare beneficiaries, it promises faster access to potentially life-changing new medical technologies. For device manufacturers, it offers greater predictability and a clearer timeline for achieving Medicare coverage, which can be a critical factor in investment and development decisions. This predictability could, in turn, foster continued innovation within the medical device industry.
However, the success and final shape of the RAPID pathway depend significantly on the public comment period. Stakeholders have until October 13, 2026, to submit feedback to CMS. This period is crucial for ensuring that the pathway effectively balances accelerated access with the need for robust evidence of clinical benefit and patient safety, especially given the Medicare population's unique health needs. CMS's call for comments indicates its commitment to an iterative process, seeking broad input to refine this important policy initiative.
